Search Results - "protective efficacy"
Search alternatives:
- "protective efficacy" »
-
1
Intranasal trivalent candidate vaccine elicits broad humoral and cellular immunity against pneumococcal pneumonia
Published 2025-06-01Subjects: Get full textStreptococcus pneumoniae is an important pathogen causing public health problems worldwide. Existing pneumococcal vaccines provide protection against only a few of the more than 100 pneumococcal serotypes, highlighting the urgent need for new preventive strategies. Pneumococcal protein vaccines have...
Article -
2
IL-24 Is a Promising Molecular Adjuvant for Enhancing Protective Immunity Induced by DNA Vaccination Against <i>Toxoplasma gondii</i>
Published 2025-07-01Subjects: Get full text<i>Toxoplasma gondii</i>, a parasitic protozoan, causes zoonotic infections with severe health impacts in humans and warm-blooded animals, underscoring the urgent need for effective vaccines to control these infections. In this study, a DNA vaccine encoding TgROP5, TgROP18, TgGRA7, TgGRA...
Article -
3
Preclinical evaluation of a live avian metapneumovirus subtype B vaccine strain with cross-protective efficacy in chickens
Published 2025-08-01Subjects: Get full textAvian metapneumovirus (aMPV) infection is an important respiratory disease that causes significant economic loss in the poultry industry. Here, we aimed to develop an effective live aMPV subtype B vaccine strain suitable for mass vaccination of poultry farms to achieve herd immunity. The wild-type v...
Article -
4
Intranasal Administration of Cold-Adapted Live-Attenuated Eurasian Avian-like H1N1 Vaccine Candidate Confers Protection Against Different-Lineage H1N1 Viruses in Mice
Published 2025-05-01Subjects: Get full textBackground/Objectives: Eurasian avian-like (EA) H1N1 swine influenza viruses, with their persistent evolution and zoonotic potential, seriously threaten both swine and human health. The objective was to develop an effective vaccine against these viruses. Methods: A cold-adapted, temperature-sensitiv...
Article -
5
Safety, immunogenicity, and protective efficacy of the intranasal live pertussis vaccine GamLPV in an infant monkey model (<i>Papio hamadryas</i>)
Published 2024-12-01Subjects: Get full textINTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after...
Article -
6
Protective efficacy of an H5/H7 trivalent inactivated vaccine produced from Re-11, Re-12, and H7-Re2 strains against challenge with different H5 and H7 viruses in chickens
Published 2020-09-01Subjects: Get full textWe developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5N6) (DK/GZ/S4184/17) (a clade 2.3.4.4d virus), A/chicken/Liaoning/SD007/2017(H5N1) (CK/LN/S...
Article -
7
An Evaluation of the Safety, Immunogenicity, and Protective Efficacy of a Combined Diphtheria–Tetanus–Acellular Pertussis, <i>Haemophilus influenzae</i> Type b, and ACYW135 Meningo...
Published 2025-07-01Subjects: Get full text<b>Background</b>: The combined diphtheria–tetanus–acellular pertussis (three-component), <i>Haemophilus influenzae</i> type b (Hib, conjugate), and ACYW135 meningococcal (conjugate) vaccine (DTaP-Hib-MCV4) offers a promising alternative to single-component vaccines, potentia...
Article -
8
Protective efficacy of an H5/H7 trivalent inactivated vaccine (H5-Re13, H5-Re14, and H7-Re4 strains) in chickens, ducks, and geese against newly detected H5N1, H5N6, H5N8, and H7N9...
Published 2022-07-01Subjects: Get full textSome H5 viruses isolated in poultry or wild birds between 2020 and 2021 were found to be antigenically different from the vaccine strains (H5-Re11 and H5-Re12) used in China. In this study, we generated three new recombinant vaccine seed viruses by using reverse genetics and used them for vaccine pr...
Article -
9
Study of the protective efficacy of CombiMab-2 against human immunodeficiency virus type 1 in mice humanised with CD4<sup>+</sup> T-lymphocytes
Published 2024-10-01Subjects: Get full textINTRODUCTION. Despite existing treatment methods, complete eradication of human immunodeficiency virus (HIV) infection remains an unattainable goal due to the high variability of HIV type 1 (HIV-1). HIV infection necessitates life-long administration of antiretroviral medicinal products, which cause...
Article